Technical Analysis for TCRX - TScan Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
NR7-2 | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Slingshot Bullish | Bullish Swing Setup | 0.90% | |
NR7 | Range Contraction | 0.90% | |
Stochastic Reached Overbought | Strength | 0.90% | |
Wide Bands | Range Expansion | 0.90% | |
Overbought Stochastic | Strength | 0.90% | |
New 52 Week High | Strength | 0.56% |
Alert | Time |
---|---|
Possible NR7 | 2 days ago |
Possible Inside Day | 2 days ago |
Up 1% | 2 days ago |
60 Minute Opening Range Breakout | 2 days ago |
Down 1% | 2 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Life Sciences Immunology Solid Tumors Immune System Health Care Hematologic Malignancies Transplantation T Cell Tumors Of The Hematopoietic And Lymphoid Tissues Preclinical Stage Biopharmaceutical Therapies For The Treatment Of Patients With Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Life Sciences Immunology Solid Tumors Immune System Health Care Hematologic Malignancies Transplantation T Cell Tumors Of The Hematopoietic And Lymphoid Tissues Preclinical Stage Biopharmaceutical Therapies For The Treatment Of Patients With Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 9.36 |
52 Week Low | 1.94 |
Average Volume | 212,408 |
200-Day Moving Average | 5.21 |
50-Day Moving Average | 7.61 |
20-Day Moving Average | 8.12 |
10-Day Moving Average | 8.48 |
Average True Range | 0.54 |
RSI (14) | 64.41 |
ADX | 21.82 |
+DI | 30.84 |
-DI | 19.44 |
Chandelier Exit (Long, 3 ATRs) | 7.74 |
Chandelier Exit (Short, 3 ATRs) | 8.27 |
Upper Bollinger Bands | 9.43 |
Lower Bollinger Band | 6.82 |
Percent B (%b) | 0.83 |
BandWidth | 32.13 |
MACD Line | 0.38 |
MACD Signal Line | 0.31 |
MACD Histogram | 0.0711 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 9.39 | ||||
Resistance 3 (R3) | 9.36 | 9.18 | 9.32 | ||
Resistance 2 (R2) | 9.18 | 9.08 | 9.20 | 9.30 | |
Resistance 1 (R1) | 9.08 | 9.01 | 9.13 | 9.12 | 9.28 |
Pivot Point | 8.91 | 8.91 | 8.93 | 8.93 | 8.91 |
Support 1 (S1) | 8.81 | 8.80 | 8.86 | 8.84 | 8.68 |
Support 2 (S2) | 8.63 | 8.74 | 8.65 | 8.66 | |
Support 3 (S3) | 8.53 | 8.63 | 8.64 | ||
Support 4 (S4) | 8.57 |